1. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. (2021) Authors: Ponce Aix, S; Novello, S; Garon, EB; Nakagawa, K; Nadal, E; Moro-Sibilot, D; Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Zimmermann, AH; Visseren-Grul, CM; Reck, M Journal: Cancer treatment and research communications Issue: Number 27(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗